Intercept Pharmaceuticals Inc (NASDAQ:ICPT) major shareholder Francesco Micheli acquired 390,625 shares of the stock in a transaction dated Monday, April 9th. The stock was acquired at an average cost of $64.00 per share, with a total value of $25,000,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their transactions with the SEC.
Shares of ICPT traded down $2.36 during midday trading on Monday, reaching $69.24. 795,712 shares of the company were exchanged, compared to its average volume of 913,680. The stock has a market cap of $1,802.36, a PE ratio of -4.82 and a beta of -1.81. Intercept Pharmaceuticals Inc has a 1-year low of $51.05 and a 1-year high of $135.59. The company has a debt-to-equity ratio of 21.71, a current ratio of 4.31 and a quick ratio of 4.31.
Intercept Pharmaceuticals (NASDAQ:ICPT) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported ($4.43) EPS for the quarter, missing the Zacks’ consensus estimate of ($3.39) by ($1.04). The company had revenue of $37.69 million for the quarter, compared to analyst estimates of $39.01 million. Intercept Pharmaceuticals had a negative return on equity of 267.95% and a negative net margin of 275.18%. The company’s revenue for the quarter was up 173.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($4.84) EPS. research analysts anticipate that Intercept Pharmaceuticals Inc will post -12.6 earnings per share for the current year.
A number of equities research analysts have recently commented on ICPT shares. Deutsche Bank started coverage on Intercept Pharmaceuticals in a research report on Tuesday, December 12th. They issued a “buy” rating and a $106.00 price objective for the company. Citigroup set a $74.00 price target on Intercept Pharmaceuticals and gave the company a “hold” rating in a research report on Thursday, December 21st. Wedbush reissued a “buy” rating and set a $253.00 price target on shares of Intercept Pharmaceuticals in a research report on Friday, December 22nd. Zacks Investment Research downgraded Intercept Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. Finally, BidaskClub downgraded Intercept Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Tuesday, January 16th. Four equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $128.75.
Several institutional investors and hedge funds have recently modified their holdings of ICPT. Bank of New York Mellon Corp lifted its stake in shares of Intercept Pharmaceuticals by 8.1% during the third quarter. Bank of New York Mellon Corp now owns 77,310 shares of the biopharmaceutical company’s stock worth $4,487,000 after purchasing an additional 5,761 shares in the last quarter. Legal & General Group Plc lifted its stake in shares of Intercept Pharmaceuticals by 48.2% during the third quarter. Legal & General Group Plc now owns 8,856 shares of the biopharmaceutical company’s stock worth $514,000 after purchasing an additional 2,882 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Intercept Pharmaceuticals during the third quarter worth about $1,567,000. Cubist Systematic Strategies LLC lifted its stake in shares of Intercept Pharmaceuticals by 68.6% during the third quarter. Cubist Systematic Strategies LLC now owns 6,717 shares of the biopharmaceutical company’s stock worth $390,000 after purchasing an additional 2,734 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. lifted its stake in shares of Intercept Pharmaceuticals by 292.0% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 7,582 shares of the biopharmaceutical company’s stock worth $440,000 after purchasing an additional 5,648 shares in the last quarter. Institutional investors own 74.27% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/09/intercept-pharmaceuticals-inc-icpt-major-shareholder-francesco-micheli-purchases-390625-shares.html.
About Intercept Pharmaceuticals
Intercept Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company’s product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions.
Receive News & Ratings for Intercept Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intercept Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.